Psychedelic Stocks Archives - Page 9 of 61

TuesdayMay 28, 2024 10:00 am

Marital Status Seems to Influence Psychedelic Outcomes, Study Shows

A recently conducted analysis has determined that people who had used psychedelics at some point in their lives experienced less psychological distress. The analysis also revealed that this link was highest in single people and significantly reduced in individuals who were married, divorced or widowed. Psychedelics are psychoactive drugs that are known to alter an individual’s mood and perception, among other things. These drugs often induce introspective experiences and powerful auditory and visual hallucinations. Classic psychedelic drugs include psilocybin, LSD, DMT and mescaline. Different studies have found positive links between psychedelic substances and health, with some highlighting the drugs’ potential…

ThursdayMay 23, 2024 10:00 am

Maryland Governor Enacts Law Creating Psychedelics Task Force

Governor Wes Moore of Maryland recently signed two measures into law that will create a task force to conduct research on legal access to psychedelics such as DMT and psilocybin. This move comes almost a month after legislators forwarded the bills to the governor’s desk. The new law will establish a task force on the responsible use of natural psychedelics that shall be overseen by the state’s Cannabis Administration. The agency will oversee the equitable, broad and affordable access to psychedelics in the state. Members of this body are tasked with assessing and making recommendations on issues such as the…

TuesdayMay 21, 2024 10:00 am

Questions Arise Regarding MAPS Research on MDMA

A few months from now, the U.S. Food and Drug Administration (FDA) will be deciding whether MDMA can be prescribed as a treatment for post-traumatic stress disorder (PTSD”. MDMA, which is commonly known as ecstasy, is currently classified as a Schedule I drug under the Controlled Substances Act. The agency’s approval of the drug’s use would be a significant breakthrough, particularly for the movement that has championed for psychedelic drugs to be used in managing a range of mental health conditions. On the other hand, FDA rejection of the drug’s use for these conditions would also be a major setback…

ThursdayMay 16, 2024 10:00 am

Vermont Lawmakers Send Modified Psychedelics Therapy Bill to Governor’s Desk

Legislators in Vermont have approved a measure that would establish a task force for psychedelic therapy. The group’s primary task would be to recommend how and whether the state should regulate legal access to psychedelic drugs such as MDMA and psilocybin. The legislation is now headed to the governor’s desk. Last week, the senate approved amended language of the legislation, approving changes made in the house. In its present form, the legislation wouldn’t amend the legal status of any drugs. Rather, the working group would review the latest evidence and research on public-health risks and benefits of clinical psychedelic-assisted therapies…

TuesdayMay 14, 2024 10:00 am

Majority of Americans That Have Used Psychedelics, Marijuana Report Positive Experiences

A survey conducted by YouGov has found that a majority of U.S. citizens have used marijuana before, and most of them revealed that the experience was a positive one. This survey also discovered that 20% of Americans have also tried “magic mushrooms” (psilocybin mushrooms), and an even bigger proportion of these users reported that the experience was a positive one. This poll comes at a time when the Biden administration is taking steps to reschedule marijuana while many states are also looking to reform their laws around psychedelics. The poll provides a deep dive into what Americans think of these…

ThursdayMay 09, 2024 10:00 am

Another Study Shows Efficacy of Psilocybin Against Depression

Depression is a leading cause of disability that affects roughly 300 million individuals around the globe. Now, new research has determined that psilocybin is an effective treatment for symptoms of depression. This is in comparison to niacin, which was administered as the placebo, and microdoses. Psilocybin is the primary active compound in more than 200 species of hallucinogenic mushrooms. The research findings, carried out by investigators in the United Kingdom, was published in the BMJ. In a statement, the researchers explained that psilocybin had shown promise in alleviating depression symptoms following the administration of one or two doses with few…

TuesdayMay 07, 2024 10:00 am

Deregulating Psychedelics Could Boost Clinical Studies

American researchers will be able to study various psychedelics and their effects on the human body much more effectively if hallucinogens are finally deregulated after decades of state and federal prohibition. Similar to how cannabis research opened up after dozens of states legalized either recreational or medical cannabis, policymakers hold the key to more comprehensive psychedelic clinical studies. Researchers typically have a significantly hard time accessing and researching controlled substances such as psychedelics, which makes them less inclined to research hallucinogenic drugs. However, with psychedelic use increasing across the country as more people turn to hallucinogens to alleviate their mental…

ThursdayMay 02, 2024 10:00 am

New Study Suggests Childhood Trauma Doesn’t Cause Challenging Ayahuasca Trips

A new study has disputed the common belief that experiencing trauma in one’s childhood may affect a user’s experience with ayahuasca. Ayahuasca is a psychoactive brew that has been used by Indigenous cultures in the Amazon and Orinoco basins for millennia for divination, spiritual ceremonies and healing. The brew is comprised of the Psychotria viridis shrub, which contains DMT, and the Banisteriopsis caapi vine. When ingested, this brew causes altered states of consciousness, which include vivid visions that can last for hours. Traditionally, these psychoactive experiences are sought for spiritual growth and healing and can be guided by experienced shamans.…

TuesdayApr 30, 2024 10:00 am

DEA Tells Court That Right to Try Law Doesn’t Supersede CSA in Psilocybin Case

The U.S. Drug Enforcement Administration (DEA) is claiming that a federal law that affords severely ill individuals the right to try investigational medications doesn’t apply to drugs classified under the Controlled Substances Act. This is in response to a lawsuit filed by a doctor in Washington state who sought permission to legally administer psilocybin as treatment for patients in end-of-life care with cancer. The agency argues that because drugs classified under Schedule I are said to have no accepted medical use, the law prevents them from being dispensed, even by professionals. The doctor in question, Dr. Sunil Aggarwal, has been…

ThursdayApr 25, 2024 10:00 am

Study Shows Ayahuasca’s Painkiller Effects in Mice, No Toxic Effects

Ayahuasca is a psychoactive brew that has been used for centuries by Indigenous cultures in South America for divination, spiritual ceremonies and healing. It is made from the Psychotria viridis shrub and the Banisteriopsis caapi vine, which contain DMT and harmala alkaloids, respectively. Interest in ayahuasca has grown in Europe and the United States over the last couple of years as people learn more about the brew’s potential therapeutic benefits in treating mental-health conditions such as anxiety, post-traumatic stress disorder and depression. Now, new research has found that the brew can be used as a painkiller without any toxic effects.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks